| Browse All

Silexion Therapeutics Corp (SLXNW)

Jerusalem, Israel | NasdaqCM
0.02 USD

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:01 a.m. EDT

Despite a recent business combination headline that might suggest renewed activity, SLXNW exhibits catastrophic failure signals: price action shows a sharp, unsupported drop from $0.03 to $0.02, the 52-week high/low are identical at $0.0207 suggesting a potential lack of distinct price history or a liquidity trap, and the company generates significant negative free cash flow (-$6.5M) with no dividends. The technical collapse from the recent close combined with negative fundamentals warrants immediate avoidance.

None
Attribute Value
Debt to Equity Ratio 78.217
Beta 0.06
Website https://silexion.com

Info Dump

Attribute Value
Address1 The Goldyne Savad Inst. of Gene Therapy
Address2 Hadassah Hebrew Univ Medical Ctr
Ask 0.0768
Ask Size 1
Beta 0.063
Book Value 0.833
City Jerusalem
Compensation As Of Epoch Date 1,735,603,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 0.0207
Current Ratio 2.406
Custom Price Alert Confidence HIGH
Day High 0.0207
Day Low 0.0207
Debt To Equity 78.217
Display Name Silexion Therapeutics
Ebitda -11,618,000
Ebitda Margins 0.0
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 972 2 643 0982
Fifty Two Week High 0.0207
Fifty Two Week High Change 0.0
Fifty Two Week High Change Percent 0.0
Fifty Two Week Low 0.0207
Fifty Two Week Low Change 0.0
Fifty Two Week Low Change Percent 0.0
Fifty Two Week Range 0.0207 - 0.0207
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 3,296,112
Free Cashflow -6,507,125
Full Exchange Name NasdaqCM
Full Time Employees 13
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,024-08-16
Language en-US
Long Business Summary Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Long Name Silexion Therapeutics Corp
Market us_market
Market State REGULAR
Max Age 86,400
Message Board Id finmb_134350646
Net Income To Common -11,912,000
Open 0.032
Operating Cashflow -10,819,000
Operating Margins 0.0
Phone 972 2 674 3430
Previous Close 0.0207
Price Hint 4
Price To Book 0.02484994
Profit Margins 0.0
Quick Ratio 2.172
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0
Regular Market Change Percent 0.0
Regular Market Day High 0.0207
Regular Market Day Low 0.0207
Regular Market Day Range 0.0207 - 0.0207
Regular Market Open 0.032
Regular Market Previous Close 0.0207
Regular Market Price 0.0207
Regular Market Time 1,776,449,374
Regular Market Volume 1,000
Return On Assets -1.44275
Sand P52 Week Change 0.34445214
Sector
Sector Key
Short Name Biomotion Sciences Warrant
Source Interval 15
Symbol SLXNW
Total Cash 5,991,000
Total Cash Per Share 1.799
Total Debt 2,036,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 1,000
Website https://silexion.com
Zip 9,112,001